[1] |
潘可达,陈为安,方慧,等.盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床研究[J].中国临床药理学杂志,2017,33(8):690-693.
|
[2] |
Hsieh TH,Huang YZ,Rotenberg A,et al.Functional dopaminergic neurons in substantia nigra are required for transcranial magnetic stimulation-induced motor plasticity[J].Cereb Cortex,2015,25(7):1806-1814.
|
[3] |
莫肇.脑蛋白水解物联合美多芭治疗帕金森病的临床疗效评价[J].现代医院,2017,17(4):564-565.
|
[4] |
Sayin S,Cakmur R,Yener GG,et al.Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson′s disease[J].J Clin Neurosci,2014,21(8):1373-1376.
|
[5] |
孙强.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察[J].解放军预防医学杂志,2016,34(S1):7.
|
[6] |
中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病的诊断标准(2016 版)[J].中华神经科杂志,2016,49(4):268-271.
|
[7] |
印美财.司来吉兰与左旋多巴联用治疗帕金森病运动障碍的临床观察[J].中西医结合心血管病杂志,2017,5(20):162-163.
|
[8] |
Filipovic SR,Rothwell JC,Bhatia K.Low-frequency repetitive transcranial magnetic stimulation and off phase motor symptoms in Parkinson′s disease[J].J Neurol Sci,2010,291(1-2):1-4.
|
[9] |
Bech P,Gram LF,Dein E,et al.Quantitative rating of depressive states[J].Acta Psychiatr Scand,1975,51(3):161.
|
[10] |
Bech P,Allerup P,Gram LF,et al.The Hamilton depression scale[J].Acta Psychiatr Scand,1981,63(3):290-299.
|
[11] |
任凤飞.美多巴联合盐酸司来吉兰治疗帕金森病的临床分析[J].中西医结合心血管病杂志,2017,5(27):183-184.
|
[12] |
Quinn L,Busse M,Bello-Haas VD.Management of upper extremity dysfunction in people with Parkinson disease and Huntington disease:facilitating outcom es across the disease lifespan[J].J Hand Ther,2013,26(2):148-155.
|
[13] |
吕荣祥.美多巴联合普拉克索治疗帕金森病的有效性及安全性研究[J].中国生化 药 物杂志,2014,34(3):154-155,159.
|
[15] |
敖文玲,胡明,方明,等.美多巴联合司来吉兰治疗帕金森病患者临床效果及安全性评价[J].国际精神病学杂志,2016,43(4):645-647.
|
[17] |
中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第 3 版)[J].中华神经科杂志,2014,47(6):428-433.
|
[14] |
Yan MH,Wang X,Zhu X.Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease[J].Free Radical Biomed,2013,62(9):90-101.
|
[16] |
Goldstein DS.Biomarkers,mechanisms,and potential prevention of catecholam in eneuron loss in Parkinson diseas[J].Adv Pharmcol,2013,68(9):235-272.
|